
Efruxifermin Shows Potential for Fibrosis Reduction in Phase 2b MASH Cirrhosis Trial
Efruxifermin, a bivalent fibroblast growth factor 21 (FGF21) analogue being developed for the treatment of metabolic dysfunction–associated steatohepatitis (MASH), failed to significantly reduce fibrosis without worsening of MASH at 36 weeks in a phase 2b …